copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
Home | Harrow, Inc. Harrow is redefining the standard of care in eyecare with a portfolio of trusted, high-value pharmaceutical solutions that deliver proven safety, efficacy, and affordability
Harrow Announces First-Quarter 2025 Financial Results Harrow, Inc (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market
SEC Filings | Harrow, Inc. The Investor Relations website contains information about Harrow, Inc 's business for stockholders, potential investors, and financial analysts
Corporate Presentation November 2025 - harrow. com Harrow was founded to advance the standard of eye care and deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes
Careers | Harrow, Inc. At Harrow, we’re always interested in connecting with talented, purpose-driven, and mission-minded individuals who share our passion for advancing eye health and improving patients’ lives
Quarterly Results | Harrow, Inc. The Investor Relations website contains information about Harrow, Inc 's business for stockholders, potential investors, and financial analysts
www. harrow. com harrow health inc-2 harrow health inc-1 harrow health inc Harrow Health INC 2,145,767 shares of common stock available for award under the Company’s 2017 Incentive Stock and Awards Plan (the “Plan) as of March 31, 2023;
Imprimis Pharmaceuticals, Inc. Acquires Intellectual . . . - Harrow, Inc. SAN DIEGO, July 23, 2013 PRNewswire -- Imprimis Pharmaceuticals, Inc (NASDAQ:IMMY), which is focused on the commercialization of drug formulations utilizing the FDA 505 (b) (2) drug development pathway, today announced that as part of the recently announced Buderer Drug Company Asset Purchase Agreement, Imprimis acquired intellectual property for IPI-120, a novel drug formulation of both